Monthly Archives
- May 2013 (4)
- April 2013 (8)
- February 2013 (4)
- January 2013 (4)
- December 2012 (1)
- September 2012 (1)
- August 2012 (1)
- July 2012 (1)
- June 2012 (1)
- May 2012 (12)
- April 2012 (2)
- March 2012 (2)
- February 2012 (2)
- January 2012 (2)
- December 2011 (3)
- November 2011 (1)
- October 2011 (4)
- September 2011 (6)
- August 2011 (7)
- July 2011 (3)
- June 2011 (4)
- May 2011 (11)
- April 2011 (8)
- March 2011 (2)
- February 2011 (8)
- January 2011 (5)
- December 2010 (5)
- November 2010 (7)
- October 2010 (24)
- September 2010 (14)
- August 2010 (4)
- July 2010 (2)
- June 2010 (1)
- March 2010 (1)
Archive | November, 2010
PPMI featured in The Lancet Neurology editorial
The Lancet Neurology offers an in-depth analysis of the value of PPMI and makes the case for the potential uses of PD biomarkers. It details the unique study design and standardization incorporated into PPMI and discusses the potential challenges that the PPMI study faces.
Continue reading...PPMI Clinical Site Recruitment Update
With almost all of the US Clinical Sites activated to recruit for PPMI, 21 subjects are enrolled in the study to date. Sites are getting off to a great start and being creative in their approaches to recruitment for the study.
Continue reading...Boston Medical Center Connection features PPMI at BMC
The BMCC highlights Boston University and the Boston Medical Center's involvement with PPMI. Dr. Sam Frank, the PI at BU, discusses the focus on and importance of biomarkers in the diagnosis and treatment of PD.
Continue reading...The Portland Physician Scribe touts PPMI at OHSU
PPMI at OHSU is profiled in The Portland Physician Scribe.
Continue reading...WQUN radio interview of Dr. Ken Marek on PPMI
Dr. Ken Marek speaks to Quinnipiac University's commercial radio station about the importance of PPMI in the field of PD.
Continue reading...Study finds that α-Synuclein is a promising biomarker for PD (Neurology)
A recent paper reports that the levels of α-synuclein oligomers and the ratio of oligomers to total α-synuclein in CSF distinguish PD cases from healthy controls and from subjects with other neurodegenerative diseases with high sensitivity and specificity.
Continue reading...Study Protocol, SOP’s, Data and Specimen Use Guidelines and Publications Policy posted
PPMI was designed with a strong focus on developing standardized protocols for collecting, transferring and storing clinical and imaging data and biological samples. The documents guiding that focus are now available online.
Continue reading...
